AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23008301 — intervention group
Group type: COMPARATOR
Intervention: Long-course (LC) chemoradiation
Number of subjects: 326
Study 19859670 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Standard Treatment (AST) - rheological therapy complemented by distraction and relaxation training
Number of subjects: 29
Study 19859670 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST) - rheological therapy
Number of subjects: 29
Study 17931375 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 seconds injection duration
Number of subjects: 50
Study 17931375 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds injection duration
Number of subjects: 50
Study 15950671 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended transdermal contraception (ORTHO EVRA) used in an extended regimen (84 days)
Number of subjects: 239
Study 15950671 — intervention group
Group type: COMPARATOR
Intervention: Traditional 28-day cyclic regimen
Number of subjects: 239
Study 15046711 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 50 mg/m2
Number of subjects: 14
Study 15046711 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 50 mg/m2 (first dose only)
Number of subjects: 14
Study 15046711 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 50 mg/m2 (subsequent cycles)
Number of subjects: 14
Study 10434821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at the P6 point
Number of subjects: 104
Study 10434821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 7572056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AED) treatment (carbamazepine, oxcarbazepine, sodium‐valproate, phenobarbital, phenytoin)
Number of subjects: 87
Study 7572056 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of AED monotherapy (carbamazepine or sodium‐valproate)
Number of subjects: 87
Study 7572056 — intervention group
Group type: COMPARATOR
Intervention: Switch from phenytoin to carbamazepine monotherapy
Number of subjects: 87
Study 2338113 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg
Number of subjects: 0
Study 2338113 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 5 mg
Number of subjects: 0
Study 2338113 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 0.2 to 5 mg
Number of subjects: 0
Study 320930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyltestosterone (10 mg daily in linguet form)
Number of subjects: 4
Study 320930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 320930 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyltestosterone
Number of subjects: 4
Study 30535714 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal autologous platelet-rich plasma injection (PRP injection group)
Number of subjects: 87
Study 30535714 — intervention group
Group type: COMPARATOR
Intervention: Submucosal normal saline injection (control group)
Number of subjects: 87
Study 28486595 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg ITM
Number of subjects: 120
Study 28486595 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg ITM
Number of subjects: 120
Study 28486595 — intervention group
Group type: COMPARATOR
Intervention: Choice of ITM dose (either 100 or 200 μg)
Number of subjects: 120
Study 25599302 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2‐mA anodal tDCS for 5 consecutive 20‐minute sessions)
Number of subjects: 48
Study 25599302 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 48
Study 25599302 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 48
Study 23009581 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP combined with (125)I seeds implantation
Number of subjects: 50
Study 23009581 — intervention group
Group type: COMPARATOR
Intervention: Regular radiation therapy
Number of subjects: 50
Study 20834105 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 16
Study 20834105 — intervention group
Group type: COMPARATOR
Intervention: FTC
Number of subjects: 16
Study 17982752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (NAC 600 mg and vitamins-minerals)
Number of subjects: 42
Study 17982752 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjunctive medical therapy)
Number of subjects: 42
Study 17982752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 42
Study 16722854 — intervention group
Group type: EXPERIMENTAL
Intervention: Contreet Foam
Number of subjects: 129
Study 16722854 — intervention group
Group type: COMPARATOR
Intervention: Allevyn Hydrocellular
Number of subjects: 129
Study 12950526 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l‐sotalol
Number of subjects: 0
Study 12950526 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐sotalol
Number of subjects: 0
Study 12950526 — intervention group
Group type: EXPERIMENTAL
Intervention: dofetilide
Number of subjects: 0
Study 12950526 — intervention group
Group type: EXPERIMENTAL
Intervention: azimilide
Number of subjects: 0
Study 10392481 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day
Number of subjects: 54
Study 10392481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 10392481 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 54
Study 8912765 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (RMP) 600 mg/d
Number of subjects: 298
Study 8912765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) 300 mg/d
Number of subjects: 298
Study 8912765 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (RMP)
Number of subjects: 298
Study 8912765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT)
Number of subjects: 298
Study 1652386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and subcutaneous salmon calcitonin
Number of subjects: 17
Study 1652386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7046707 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment group
Number of subjects: 0
Study 7046707 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0
Study 31740551 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus temozolomide (arm A, CAPTEM)
Number of subjects: 86
Study 31740551 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI (arm B)
Number of subjects: 86
Study 28371488 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative film‐coated warfarin sodium tablets
Number of subjects: 24
Study 28371488 — intervention group
Group type: COMPARATOR
Intervention: Marketed sugar‐coated warfarin sodium tablets
Number of subjects: 24
Study 27397586 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy
Number of subjects: 74
Study 27397586 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 74
Study 27397586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 74
Study 27397586 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 74
Study 24094827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery with normo-glycemia after hypoglycemia
Number of subjects: 43
Study 24094827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia
Number of subjects: 43
Study 24094827 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery with hyperglycemia after hypoglycemia with vitamin C infusion
Number of subjects: 43
Study 21968280 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training program (mini mp3 player with 13-min relaxation audio program, followed daily)
Number of subjects: 127
Study 21968280 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (control group)
Number of subjects: 127
Study 20089825 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clozapine (Gen-Clozapine)
Number of subjects: 0
Study 20089825 — intervention group
Group type: COMPARATOR
Intervention: Clozaril
Number of subjects: 0
Study 18232722 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 325
Study 16805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Live interactive music
Number of subjects: 32
Study 16805928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-recorded music
Number of subjects: 32
Study 16805928 — intervention group
Group type: COMPARATOR
Intervention: Silence (placebo)
Number of subjects: 32
Study 14762496 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1.0 mg/kg)
Number of subjects: 11
Study 14762496 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.75 mg/kg) plus Hydroxyzine (2.0 mg/kg)
Number of subjects: 11
Study 14762496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10800814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivostat fibrin sealant
Number of subjects: 30
Study 10800814 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 30
Study 8846278 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Analgesia (PCA)
Number of subjects: 30
Study 8846278 — intervention group
Group type: COMPARATOR
Intervention: Continuous Morphine Infusion (CMI)
Number of subjects: 30
Study 1999715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during chemotherapy administration
Number of subjects: 95
Study 1999715 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cryotherapy)
Number of subjects: 95
Study 6542398 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 72
Study 6542398 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg/kg
Number of subjects: 72
Study 6542398 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 15 mg/kg
Number of subjects: 72
Study 30682128 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading abstracts with overstatement
Number of subjects: 567
Study 30682128 — intervention group
Group type: COMPARATOR
Intervention: Reading abstracts without overstatement
Number of subjects: 567
Study 29703606 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab with Best Supportive Care (BSC)
Number of subjects: 270
Study 29703606 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 270
Study 26968520 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex, multifaceted intervention including healthcare professional education, local concertation, and interdisciplinary case conferences.
Number of subjects: 2205
Study 26968520 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 2205
Study 24945286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (808 nm laser irradiation as 4 J/point for 20 s over ipsilateral three nerve roots and 0.1 J/cm2 for 5 min in tangential scanning mode)
Number of subjects: 48
Study 24945286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 48
Study 24945286 — intervention group
Group type: COMPARATOR
Intervention: Control group (lidocaine-only)
Number of subjects: 48
Study 22737868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanchi Tong Shu capsule
Number of subjects: 206
Study 22737868 — intervention group
Group type: COMPARATOR
Intervention: Betahistine mesilate tablets
Number of subjects: 206
Study 21195985 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) insufflation under deep sedation
Number of subjects: 104
Study 21195985 — intervention group
Group type: EXPERIMENTAL
Intervention: Air insufflation under deep sedation
Number of subjects: 104
Study 21195985 — intervention group
Group type: COMPARATOR
Intervention: CO(2) insufflation under conscious-sedation
Number of subjects: 104
Study 21195985 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation under conscious-sedation
Number of subjects: 104
Study 21195985 — intervention group
Group type: COMPARATOR
Intervention: CO(2) insufflation under awake
Number of subjects: 104
Study 21195985 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation under awake
Number of subjects: 104
Study 17435545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental training
Number of subjects: 98
Study 17435545 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 98
Study 17435545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 98
Study 16050412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0
Study 16050412 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental calcium (max 1000 to 1500 mg/day)
Number of subjects: 0
Study 16050412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0
Study 16050412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate, colestilan, and nicotinamide
Number of subjects: 0
Study 12813472 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 82
Study 12813472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 10392964 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 10392964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (clinical trial)
Number of subjects: 0
Study 10392964 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (matched controls)
Number of subjects: 0
Study 10392964 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (matched to tacrolimus group)
Number of subjects: 0
Study 10392964 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (matched to cyclosporine group)
Number of subjects: 0
Study 8699054 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of RRV‐TV vaccine
Number of subjects: 0
Study 8699054 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of RRV‐TV vaccine
Number of subjects: 0
Study 8699054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8699054 — intervention group
Group type: EXPERIMENTAL
Intervention: One and three doses of RRV‐TV vaccine
Number of subjects: 0
Study 2021564 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual for smoking cessation
Number of subjects: 745
Study 2021564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 745
Study 7044294 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of amantadine
Number of subjects: 52
Study 7044294 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of rimantadine
Number of subjects: 52
Study 7044294 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine
Number of subjects: 52
Study 7044294 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of amantadine + 4 mg of chlorpheniramine
Number of subjects: 52
Study 7044294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30941562 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg
Number of subjects: 137
Study 31829173 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanxinshutong (GXST) capsules
Number of subjects: 300
Study 31829173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 29609146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapeutic intervention based on cognitive‐behavioral therapy (CBT); 8 weekly, semi‐structured group meetings.
Number of subjects: 47
Study 27055643 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.03 mg/kg) and Atropine (0.01 mg/kg)
Number of subjects: 160
Study 27055643 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.1 ml/kg)
Number of subjects: 160
Study 24138922 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine challenge in high-risk group
Number of subjects: 16
Study 24138922 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine challenge in stimulant drug-naïve healthy control subjects
Number of subjects: 16
Study 24138922 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine challenge in subjects matched to high-risk group on personal drug use
Number of subjects: 16
Study 22578529 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin (1200 mg daily)
Number of subjects: 10
Study 22578529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19462315 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 8
Study 19462315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17468814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (neutrophil elastase inhibitor)
Number of subjects: 13
Study 17468814 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 16421344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy diet (HD) with acute energy deficit
Number of subjects: 19
Study 16421344 — intervention group
Group type: COMPARATOR
Intervention: Low-dairy diet (LD) with acute energy deficit
Number of subjects: 19
Study 16421344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dairy diet (HD) under energy balance
Number of subjects: 19
Study 16421344 — intervention group
Group type: COMPARATOR
Intervention: Low-dairy diet (LD) under energy balance
Number of subjects: 19
Study 11913291 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide tooth-whitening gel strip, used for 30 minutes per day, twice daily for 2 months
Number of subjects: 0
Study 9818805 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz electroacupuncture with needles inserted into the appropriate point in each ear
Number of subjects: 76
Study 9818805 — intervention group
Group type: COMPARATOR
Intervention: Sham control procedure over the mastoid bone
Number of subjects: 76
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 25 mg
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 200 mg
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 100 mg three times a day for 6 days plus once a day on the 7th day
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a 50 mg every 12 h for 13 doses
Number of subjects: 36
Study 7695301 — intervention group
Group type: EXPERIMENTAL
Intervention: DU-6859a (all doses)
Number of subjects: 36
Study 2468957 — intervention group
Group type: EXPERIMENTAL
Intervention: isradipine 5-10 mg twice daily
Number of subjects: 16
Study 2468957 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 407914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal feeding of water, electrolytes, protein, and calories
Number of subjects: 0
Study 407914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) feeding of amino acids and calories
Number of subjects: 0
Study 407914 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal tract feeding of protein and calories
Number of subjects: 0
Study 30664548 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (n = 145): tidal volume 6 ml/kg of ideal body weight, individualized PEEP to minimize driving pressure.
Number of subjects: 292
Study 30664548 — intervention group
Group type: COMPARATOR
Intervention: Conventional protective ventilation (n = 147): tidal volume 6 ml/kg of ideal body weight, PEEP 5 cm H2O, and recruitment maneuver.
Number of subjects: 292
Study 30664548 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation (n = 145)
Number of subjects: 292
Study 30664548 — intervention group
Group type: COMPARATOR
Intervention: Conventional protective ventilation (n = 147)
Number of subjects: 292
Study 27901287 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 100
Study 27901287 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy
Number of subjects: 100
Study 25746399 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (51%-70% of predicted HR(max))
Number of subjects: 87
Study 25746399 — intervention group
Group type: COMPARATOR
Intervention: Sedentary behavior
Number of subjects: 87
Study 25746399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (volume of maximum oxygen consumption)
Number of subjects: 87
Study 24010572 — intervention group
Group type: EXPERIMENTAL
Intervention: 80/480 mg tablet
Number of subjects: 120
Study 24010572 — intervention group
Group type: EXPERIMENTAL
Intervention: 60/360 mg tablet
Number of subjects: 120
Study 24010572 — intervention group
Group type: COMPARATOR
Intervention: Four standard tablets
Number of subjects: 120
Study 24010572 — intervention group
Group type: COMPARATOR
Intervention: Three standard tablets
Number of subjects: 120
Study 21324142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant imatinib (IM) treatment
Number of subjects: 25
Study 21324142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection after neoadjuvant IM
Number of subjects: 25
Study 21324142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection followed by continuous IM treatment
Number of subjects: 25
Study 21324142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection followed by IM
Number of subjects: 25
Study 18851855 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 0.6 g per day plus 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 280
Study 18851855 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 17-hydroxyprogesterone caproate (17-OHPC)
Number of subjects: 280
Study 16966303 — intervention group
Group type: EXPERIMENTAL
Intervention: A. fumigatus challenge
Number of subjects: 27
Study 15457023 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthecal digital block
Number of subjects: 50
Study 15457023 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infiltration block
Number of subjects: 50
Study 11726254 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TRN)
Number of subjects: 20